Bethany Hills spoke to Modern Healthcare about the Food and Drug Administration’s postponement of overseas inspections, which will financially drain drug and devicemakers and may compromise products’ quality.
“The financial impact is not just related to getting a product on the market, it is about the long haul of launching a product,” Bethany said. “The part people really struggle with is if they keep all their sales staff, keep hiring, or hold off. How do you tread water and be ready to go at a moment’s notice without knowing when that moment will come?”
Read the full article.